

Synergism of Phage **\phiPT1b** and Antibiotics for Reducing Infection of *Escherichia coli*

ERLIA NARULITA^{1,2*}, GERDA PERMATA AJI^{1,2}, BEVO WAHONO^{1,3}, SITI MURDIYAH¹, RIA YULIAN^{1,2}

¹Study program of Biology Education, Faculty of Teacher Training and Education, University of Jember Jl. Kalimantan No.37, Jember, East Java, Indonesia. 68121

*Email: erlia.fkip@unej.ac.id

²Center for Development of Advanced Science and Technology, University of Jember

Jl. Kalimantan No.37, Jember, East Java, Indonesia. 68121

³National Taiwan Normal University,

Ting-chou Rd, Sec 4, Taipei, Taiwan, 11677

Received 30 November 2019; Received in revised form 07 March 2020; Accepted 14 May 2020; Available online 30 June 2020

ABSTRACT

Foodborne disease caused by *Escherichia coli* contamination is increasing every year. It also followed by elevating of drug-resistance of *E. coli*. Bacteriophage can be an alternative for therapy infection. This study aimed to determine synergism effect of bacteriophage ϕ PT1b which has a high rate virulence to *E. coli* and phage-antibiotics (tetracycline and amoxicillin) synergy. The indigenous bacteria isolates were KR, MJ, KP, PT, PR. Five bacteriophages used namely ϕ KR1b, ϕ KR2, ϕ PT1a, ϕ PT1b, and ϕ MJ1b. Virulence test was used to determine the ability of each phage in reducing *E. coli*. Treatment to examine synergism of phage ϕ PT1b and antibiotics were P1: amoxicillin, P2: ϕ PT1b, P3: ϕ PT1b + Amx = 1:1, P4 : ϕ PT1b + Amx = 2:1, P5: ϕ PT1b + Amx = 1:2, P6 : tetracycline, P2: ϕ PT1b, P7: ϕ PT1b + Tet = 1:1, P8 : ϕ PT1b + Tet = 2:1, and P9: ϕ PT1b + Tet = 1:2. The virulence test showed that isolate ϕ PT1a with 106 CFU/ml had the highest ability in reducing *E. coli*. While, the result of synergism test indicated that the synergism of bacteriophage and antibiotics differ significantly (P ≤ 0.05). The best ratios of synergism were 1:1 (ϕ PT1b+tetracycline) and 2:1 (ϕ PT1b+amoxicilline). In summarize, phage-antibiotic synergy (ϕ PT1b with tetracycline/amoxicilline) can reduce the level of antibiotic resistance in isolated *E. coli*.

Keywords: amoxicillin; bacteriophage; phage-antibiotic synergy; tetracycline; virulence abilities

INTRODUCTION

Foodborne disease is caused by food consumption. contaminated Contamination happens during preparation and serving process; it poses threats to health in general (Ameme et al., 2016). One type of food prone to bacterial contamination is vegetables (Quinlan, 2013). Campylobacter (Verhoeff-Bakkenes et al., 2011; Mohammadpour et al., 2018), Salmonella (de Freitas Neto et al., 2010; Golberg et al., 2011), Shigella (Ranjbar et al., 2010; Magnone et al., 2013), Listeria (Ponniah et al., 2010; Oliveira et al., 2011), Yersinia (Xanthopoulos et al., 2010; Tirziu et al., 2011) and Escherichia coli (Harapas et al., 2010; Ijabadeniyi et al., 2011; Uzeh & Adepoju, 2013) are among the common bacteria contaminate vegetables.

Pathogenic *E. coli* are the dominant cause of diarrhea which is the primary indicator of food poisoning. The symptoms can be severe and fatal. Diarrhea-caused *E. coli* can be divided into several types, including enterotoxic *E. coli* (ETEC), enteropathogenic *E. coli* (EPEC), enteroinvasive *E. coli* (EIEC), and enterohaemorrhagic *E. coli* (EHEC). In addition, a uropathogenic *E. coli* can infect extraintestinal and causing urinary tract infections. Some of these strains can cause foodborne disease (Caine *et al.*, 2014).

Typical treatment for foodborne disease is using antibiotics, but now antibiotics pose a new problem, which is an increase in the incidence of antibiotics resistance. Antibiotic resistance is characterized by failure inhibition of bacterial growth (Andersson & Hughes, 2010; Humaida, 2014; Brown & Wright, 2016). *E. coli* show antibiotic resistance in all β -lactam antibiotics, tetracycline, and in cephalothin and cefoxitin from cephalosporins (Sidik *et al.*, 2016). Another alternative treatment for foodborne disease is using bacteriophages (phages). Bacteriophage is a virus that can infect and kill bacterial cells. The presence of bacteriophages that can kill these hosts can be applied in the technology of the lytic process for biofilm-forming bacteria (Buana & Wardani, 2013). Bacteriophages have a tiny size, in nanometers, and live in the same place as the bacterial host. Bacteriophages have speciesspecific properties and even in strains that can only infect bacteria that are like their hosts (Hamdi *et al.*, 2017).

Phage therapy has proven effective for controlling pathogens that cause foodborne disease both preand post-harvest. Administration of phages in pre- and postharvest can control the contamination of bacteria such as E. coli O157: H7, Salmonella, and Campylobacter in food products. The use of phages in pre-harvest to reduce pathogens is carried out directly by providing phages to the plants, while the administration of phages in the post-harvest is carried out directly to eliminate unwanted contaminants in food products that are ready to be consumed (Teng-Hern et al., 2014).

Phages biocontrol have as several advantages such as the ability to attack bacteria and zero influence on other cell types including human, animal and plant cells. This is as reported in the ϕ ECP100 and ϕ AHFAHEc1 tests carried out as natural preservatives of fresh vegetables and meat products contaminated by E. coli O157: H7. Test results showed that bacteriophage *\phi*ECP100 and *\phi*AHFAHEc1 could eliminate contamination of E. coli in raw beef (Lee et al., 2017). In other studies, φVCEV1 can also infect E. coli O157: H7 where this bacteriophage has a 70 nm icosahedral head shape and a long flexible tail measuring 175 nm in length and 10 nm in width with a genome size of 120 kb (Raya et al., 2015).

Another advantage of bacteriophages is that it can reduce the resistance of pathogenic bacteria to antibiotics. Combinations between bacteriophages and antibiotics usually referred to as phage-antibiotic synergy (PAS). In ϕ KS12 and ϕ KS14 with a combination of ciprofloxacin, meropenem, and tetracycline can kill *Burkholderia cepacia* thus it can reduce the resistance properties of Burkholderia cepacia against antibiotics (Kamal & Dennis, 2015; Sfeir, 2018). In a previous study, isolated five bacteriophages from E. coli contaminating vegetables in the Jember Regency (Narulita et al., 2018). The five bacteriophages have not been known of the ability to perform PAS including bacteriophage ϕ PT1a that have a high virulence rate. This study aimed to determine synergism effect of bacteriophage ϕ PT1a which has a high rate virulence to E. coli and phageantibiotics (tetracycline and amoxicillin) synergy.

MATERIALS AND METHODS

Sample Preparation. Bacteria were grown in eosin methylene blue agar (EMBA) to determine whether the bacteria used were isolates of Escherichia coli PT (Tanjung Market), KR (Kreongan Market), MJ (Peddler), KP (Kepatihan Market), PR (Patrang Market). In EMBA, E. coli PT (Tanjung Market), KR (Kreongan Market), MJ (Peddler), KP (Kepatihan Market), PR (Patrang Market) give characteristics of metallic green colonies. For further treatment luria bertani (LB) medium was used. The incubation was carried out for 24 hours at 37°C. Particles of phages were multiplied by plaque assay techniques 100 µl of each filtrate following. А bacteriophage of φKR1a, φKR1b, φPT1a, φPT1b, φMJ1b and φKR2 suspension added into 250 µl of E. coli suspension which had been incubated for 2 hours at 37°C. The suspension was mixed with warm (around 50°C) top agar medium, and then poured on LB. The petri dish was incubated at 37°C for 24 hours. The colonies of phage were indicated in the formation of plaques. SM buffers as much as 5 ml were added to acquire the phages. The media were shaken for 4 hours at 4°C and then were centrifuged for 10 minutes at 10000 rpm. The phages were harvested using a membrane filter with a pore membrane density of $0.2 \,\mu m$. The filtrate served as bacteriophage stock (Askora et al., 2009).

Virulence Assay. The test was carried out using the plaque assay technique (Askora *et al.*, 2009). A 300 μ l suspension of 5 hours *E. coli* and, 3 μ l phage suspension was added to the

0.3% warm top medium. The mixture then was poured on the surface of LB agar media in a petri dish (double layer method). Incubation carried out at 37°C for 24 hours. The growth of phages was observed by counting the formation of plaque. Different concentrations were used for each type of phage suspension i.e 102, 104, and 106 of phages suspension.

Virulence Assay of phage + antibiotic to the growth of *E. coli*. The technique to find out the strength of phage+antibiotic virulence was using spot test technique according to (Narulita *et al.*, 2018). A 300 µl suspension of 5 hours *E. coli* (0.1 U of OD600) and 3 µl bacteriophage suspension was added to the 0.3% warm top medium. The mixture then was poured on the surface of LB agar medium in a petri dish (double layer method). Next, 3 µl of the phage+3 µl antibiotic suspension was spotted on the LB agar medium and incubated at 37°C for 24 hours. Growth was observed with the formation of plaque with six replications. Serial of phage concentration was used which gave the maximum results in the previous test (virulence test without antibiotics).

Bacteriophages used in the phageantibiotic synergy (PAS) test was ϕ PT1a that has a highest virulence rate in infecting *E. coli* isolates. The antibiotics used were amoxicillin (Amx) and tetracycline (Tet). The treatment was divided into P1: amoxicillin, P2: ϕ PT1b, P3: ϕ PT1b + Amx = 1:1, P4 : ϕ PT1b + Amx = 2:1, P5: ϕ PT1b + Amx = 1:2, P6 : tetracycline, P2: ϕ PT1b, P7: ϕ PT1b + Tet = 1:1, P8 : ϕ PT1b + Tet = 2:1, and P9: ϕ PT1b + Tet = 1:2. The effect of this test results determined by analysis of variants (ANOVA) of 95% confidence level (p <0.05), then followed by Duncan's test.

RESULT AND DISCUSSION

Each phage has different virulence abilities. From three different phage concentrations of 10^2 , 10^4 , 10^6 (CFU/ml) of each tested bacteriophage, ϕ PT1b gave the highest result of infection to *E. coli* at concentration of 10^6 CFU/ml (Figure 1 and 2) compared to other bacteriophages.



Figure 1. The number of phage on plaque assay with Escherichia coli

The combination between phage and amoxicillin showed different results that in treatment P4 gave higher efficiency than the others, P2 had a higher level of infection than amoxicillin whereas P7 was a combination of phage and tetracycline indicating that P7 had a higher effectiveness (Table 1 and 2).

Virulence test used amoxicillin and tetracycline because both types of antibiotics

performed resistance to *E. coli*. In the treatment area that only used antibiotics, no plaque was formed. This result showed no growth inhibition in *E. coli* (resistance occurred). The resistance occurs due to biochemical modifications that alter the nature of bacteria from those that are usually sensitive to antibiotics to become insensitive.



Figure 2. Virulence test results of phage combination: a. amoxicillin antibiotics with treatment P1: amoxicillin, P2: φPT1b, P3: φPT1b + Amx = 1:1, P4: φPT1b + Amx = 2:1, P5: φPT1b + Amx = 1:2; b. tetracyclin with treatment P6: tetrasiklin, P2: φPT1b, P7: φPT1b + Tet = 1:1, P8: φPT1b + Tet = 2:1, P9: φPT1b + Tet = 1:2.

The chemical modification that occurs can be an enzyme that deactivates antibiotic receptors and changes in protein in the cell wall that inhibit the absorption of these antibiotics. The existence of genetic mechanisms in the form of mutations and transformations can also trigger antibiotic resistance. Mutations may occur naturally during cell division. The more cells undergo replication, the higher the chance for mutation. Mutations that occur may encode a new resistance gene to deactivate antibiotic receptors (Andersson & Hughes, 2014; Blount, 2015). Plaque can be found in the treatment area that uses a combination of antibiotics and phages (Figure 2). On the other hand, the bacteriophage virulence test showed that ϕ PT1b was able to infect bacteria higher than the other phages at a concentration of 10^6 CFU/ml (Figure 1).

Average of Plaque Diameter (mm)
0.00 ± 0.0^{a}
$1.50 \pm 0.22^{\circ}$
$1.31 \pm 0.29^{\rm bc}$
$1.41\pm0.21^{ m bc}$
1.19 ± 0.14^{b}
0.00 ± 0.0
-

Table 1. The result of virulence assay for phage + amoxicillin combination to E. coli

Notes: P1 : amoxicillin (Amx), P2 : ϕ PT1b, P3 : Phage + Amx= 1:1, P4 : Phage + Amx= 2:1, P5: Phage + Amx= 1:2. The same letter in the same column indicates not significantly different by Duncan test using α 5%

Treatments	Average of Plaque Diameter (mm)
P6	$0.00\pm0.00^{\mathrm{a}}$
P2	$1.50 \pm 0.22^{\circ}$
P7	$1.36\pm0.21^{\mathrm{b}}$
P8	$1.30\pm0.12^{\mathrm{b}}$
P9	$1.23\pm0.25^{\mathrm{b}}$
К-	0.00 ± 0.00

Notes: P2 : ϕ PT1b, P6 : Tetracyclin (Tet), P7 : Phage + Tet = 1:1, P8 : Phage + Tet = 2:1, P9 : Phage + Tet = 1:2. The same letter in the same column indicates not significantly different by Duncan test using α 5%

The results of virulence test of phageantibiotics combinations gave different results between the two types of antibiotics. The treatment of P2, P3, P4, P5, P7, P8 and P9 were significantly different from P1 and P6 (Table 1 and Table 2). In the combination of phage with amoxicillin, it showed that P4 gave higher virulence effectiveness than P3 and P5 (Table 1). While the combination of phage with tetracycline indicated that the P7 treatment has higher effectiveness compared to P8 and P9 (Table 2). P2 treatment which was phage ϕ PT1b only, it turned out to have the highest infection rate compared to the combination with amoxicillin and tetracycline (Table 1 and 2). Large clear zones formed for both types of antibiotic combinations can be seen in Figure 2.

The difference in plaque size is due to the replication process of phages that produce new plaques (Bhardwaj *et al.*, 2015). The more phages produced will have larger plaque sizes, and vice versa, if the fewer phages are produced, then the size plaque will get smaller too. The resulting plaque size is determined by the number of virions produced in each infected cell and how long it takes for bacteriophages to lyse infected cells (Comeau *et al.*, 2007).

When phages and antibiotics are combined, there is a possibility of phage mutant that lyses bacteria faster and can make plaque formation more quickly than the parent bacteriophage. Antibiotics also have the same working time as bacteriophages, hence a combination of bacteriophages and antibiotics can inhibit the growth of pathogenic bacterial cells (Golkar et al., 2014; Tagliaferri et al., Similar research was conducted, 2019). regarding bacteriophage therapy to control pathogenic *Pseudomonas* aeruginosa by combining antibiotics and bacteriophages (Torres-Barceló et al., 2014). The results showed that the combination of streptomycin and bacteriophages results in a positive synergy that inhibits the growth of Pseudomonas aeruginosa. T4 type phages could also be combined with cefotaxime type antibiotics Comeau et al. (2007) found there was positive synergy marked by the reduction of *E. coli* cell production. The presence of phage-antibiotic synergy (PAS) response is seen with the formation of clear zones which indicate that chemicals in antibiotics stimulate phage growth at the same level as the conditions of antibiotics when inhibiting bacterial cell division.

CONCLUSION

Phage-antibiotic synergy (ϕ PT1b with tetracycline/amoxicilline) can reduce the level of antibiotic resistance in isolated *E. coli*.

REFERENCES

Ameme DK, Abdulai M, Adjei EY, Afari EA, Nyarko KM, Asante D, Kye-Duodu G, Abbas M, Sackey S,

Wurapa F. 2016. Foodborne disease outbreak in a resource-limited setting: a tale of missed opportunities and implications for response. *Pan African Medical Journal*. vol 23(1): 1-9. doi: https://doi.org/10.11604/pamj.2016.23.69.7660.

- Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance?. *Nature Reviews Microbiology*. vol 8(4): 260-271. doi: https://doi.org/10.1038/nrmicro2319.
- Andersson DI, Hughes D. 2014. Microbiological effects of sublethal levels of antibiotics. *Nature Reviews Microbiology*. vol 12(7): 465-478. doi: https://doi.org/10.1038/nrmicro3270.
- Askora A, Kawasaki T, Usami S, Fujie M, Yamada T. 2009. Host Recognition and Integration of Filamentous Phage ϕ RSM in the Phytopathogen, Ralstonia solanacearum. *Virology*. vol 384(1): 69-76. doi: https://doi.org/10.1016/j.virol.2008.11.007.
- Bhardwaj N, Bhardwaj SK, Deep A, Dahiya S, Kapoor S. 2015. Lytic bacteriophages as biocontrol agents of foodborne pathogens. *Asian journal of animal and veterinary advances*. vol 10(11): 708-723. doi: http://dx.doi.org/10.3923/ajava.2015.708.723.
- Blount ZD. 2015. The natural history of model organisms: The unexhausted potential of *E. coli*. *Elife*. vol 4: 1-12. doi: http://dx.doi.org/10.7554/eLife.05826.001.
- Brown ED, Wright GD. 2016. Antibacterial drug discovery in the resistance era. *Nature*. vol 529(7586): 336-343. doi: https://doi.org/10.1038/nature17042.
- Buana EOGHN, Wardani AK. 2013. Isolasi Bakteriofag Litik Sebagai Agen Biosanitasi Pada Proses Pelisisan Bakteri Pembentuk Biofilm. Jurnal Pangan dan Agroindustri. vol 2(2): 36-42.
- Caine LA, Nwodo UU, Okoh AI, Ndip RN, Green E. 2014. Occurrence of virulence genes associated with diarrheagenic *Escherichia coli* isolated from raw cow's milk from two commercial dairy farms in the Eastern Cape Province, South Africa. *International Journal of Environmental Research and Public Health.* vol 11(11): 11950-11963. doi: https://doi.org/10.3390/ijerph111111950.
- Comeau AM, Tétart F, Trojet SN, Prère MF, Krisch HM. 2007. Phage-Antibiotic Synergy (PAS): β-Lactam and quinolone antibiotics stimulate virulent phage growth. *Plos One.* vol 2(8): 1-4. doi: https://dx.doi.org/10.1371%2Fjournal.pone.00007 99.
- de Freitas Neto OC, Penha Filho RAC, Barrow P, Berchieri Junior A. 2010. Sources of human nontyphoid salmonellosis: a review. *Brazilian Journal of Poultry Science*. vol 12(1): 1-11. doi: https://doi.org/10.1590/S1516-635X2010000100001.
- Golberg D, Kroupitski Y, Belausov E, Pinto R, Sela S. 2011. Salmonella typhimurium internalization is variable in leafy vegetables and fresh herbs. International journal of food microbiology. vol 145(1): 250-257. doi:

https://doi.org/10.1016/j.ijfoodmicro.2010.12.031.

- Golkar Z, Bagasra O, Pace DG. 2014. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. *The Journal of Infection in Developing Countries.* vol 8(2): 129-136. doi: https://doi.org/10.3855/jidc.3573.
- Hamdi S, Rousseau GM, Labrie SJ, Tremblay DM, Kourda RS, Slama KB, Moineau S. 2017. Characterization of Two Polyvalent Phages Infecting Enterobacteriaceae. *Scientific Reports.* vol 7(1): 1-12. doi: https://doi.org/10.1038/srep40349.
- Harapas D, Premier R, Tomkins B, Franz P, Ajlouni S. 2010. Persistence of *Escherichia coli* on injured vegetable plants. *International journal of food microbiology*. vol 138(3): 232-237. doi: https://doi.org/10.1016/j.ijfoodmicro.2010.01.022.
- Humaida R. 2014. Strategy to handle resistance of antibiotics. *Jurnal Majority*. vol 3(7): 113-120.
- Ijabadeniyi OA, Debusho LK, Vanderlinde M, Buys EM. 2011. Irrigation water as a potential preharvest source of bacterial contamination of vegetables. *Journal of Food Safety*. vol 31(4): 452-461. doi: https://doi.org/10.1111/j.1745-4565.2011.00321.x.
- Kamal F, Dennis JJ. 2015. *Burkholderia cepacia* complex phage-antibiotic synergy (PAS): antibiotics stimulate lytic phage activity. *Applied and environmental microbiology*. vol 81(3): 1132-1138. doi: 10.1128/AEM.02850-14.
- Lee H, Ku HJ, Lee DH, Kim YT, Shin H, Ryu S, Lee JH. 2016. Characterization and Genomic Study of the Novel Bacteriophage HY01 Infecting Both *Escherichia coli* O157:H7 and *Shigella flexneri*: Potential as a Biocontrol Agent in Food. *Plos One*. vol 11(12): 1-21. doi: https://doi.org/10.1371/journal.pone.0168985.
- Magnone JP, Marek PJ, Sulakvelidze A, Senecal AG. 2013. Additive approach for inactivation of *Escherichia coli* O157: H7, *Salmonella*, and *Shigella* spp. on contaminated fresh fruits and vegetables using bacteriophage cocktail and produce wash. *Journal of food protection*. vol 76(8): 1336-1341. doi: https://doi.org/10.4315/0362-028X.JFP-12-517.
- Mohammadpour H, Berizi E, Hosseinzadeh S, Majlesi M, Zare M. 2018. The prevalence of *Campylobacter* spp. in vegetables, fruits, and fresh produce: a systematic review and meta-analysis. *Gut pathogens*. vol 10(1): 1-12. doi: https://doi.org/10.1186/s13099-018-0269-2.
- Narulita E, Sulistyorini I, Aji GP, Iqbal M, Murdiyah S. Isolation and characterization of bacteriophage in controlling *Escherichia coli* in Jember Area, Indonesia. 2018. *Asian Journal of Microbiology*, *Biotechnology, and Environmental Sciences.* vol 20(2): 439-444.
- Oliveira M, Usall J, Viñas I, Solsona C, Abadias M. 2011. Transfer of Listeria innocua from contaminated compost and irrigation water to lettuce leaves. *Food microbiology*. vol 28(3): 590-

596. doi: https://doi.org/10.1016/j.fm.2010.11.004.

- Ponniah J, Robin T, Paie MS, Radu S, Ghazali FM, Kqueen CY, Nishibuchi M, Nakaguchi Y, Malakar PK. 2010. Listeria monocytogenes in raw salad vegetables sold at retail level in Malaysia. *Food Control.* vol 21(5): 774-778. doi: https://doi.org/10.1016/j.foodcont.2009.09.008
- Ranjbar R, Hosseini MJ, Kafashian A, Farshad SH. 2010. An outbreak of shigellosis due to Shigella flexneri serotype 3a in a prison in Iran. Archives of Iranian Medicine. vol 13(5): 413-416. doi: https://dx.doi.org/010135/AIM.008.
- Raya RR, Oot RA, Moore-Maley B, Wieland S, Callaway TR, Kutter EM, Brabban AD. 2011. Naturally resident and exogenously applied T4-like and T5-like bacteriophages can reduce Escherichia coli O157: H7 levels in sheep guts. *Bacteriophage*. vol 1(1): 15-24. doi: https://doi.org/10.4161/bact.1.1.14175.
- Sfeir MM. 2018. Burkholderia cepacia complex infections: more complex than the bacterium name suggest. *Journal of Infection*. vol 77(3): 166-170. doi: https://doi.org/10.1016/j.jinf.2018.07.006.
- Sidik KR, Lukman DW, Wibawan IWT. 2016. Cemaran Escherichia coli pada Tepung Telur yang diimpor Melalui Pelabuhan Tanjung Priok, dan Resistensinya Terhadap Antibiotik. Jurnal vol 17(2): 235-245. Veteriner. doi: https://doi.org/10.19087/jveteriner.2016.17.2.235.
- Tagliaferri TL, Jansen M, Horz HP. 2019. Fighting pathogenic bacteria on two fronts: Phages and antibiotics as combined strategy. *Frontiers in Cellular and Infection Microbiology*. vol 9: 1-12. doi: https://doi.org/10.3389/fcimb.2019.00022.
- Teng-Hern TL, Kok-Gan C, Han LL. 2014. Application of Bacteriophage in Biocontrol of Major Foodborne Bacterial Pathogens. *Journal of Molecular Biology and Molecular Imaging*. vol 1(1): 2471-0237.
- Tirziu E, Cumpanasoiu C, Gros RV, Seres M. 2011. Yersinia enterocolitica monographic study. *Scientific Papers Animal Science and Biotechnologies.* vol 44(2): 144-149.
- Torres-Barceló C, Arias-Sánchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME. 2014. A window of opportunity to control the bacterial pathogen *Pseudomonas aeruginosa* combining antibiotics and phages. *PloS one.* vol 9(9): 1-7. doi: https://doi.org/10.1371/journal.pone.0106628.
- Uzeh RE, Adepoju A. 2013. Incidence and survival of *Escherichia coli* O157: H7 and Listeria monocytogenes on salad vegetables. *International food research journal*. vol 20(4): 1921-1925.
- Quinlan JJ. 2013. Foodborne illness incidence rates and food safety risks for populations of low socioeconomic status and minority race/ethnicity: a review of the literature. *International journal of environmental research and public health*. vol 10(8): 3634-3652. doi: https://doi.org/10.3390/ijerph10083634.

Verhoeff-Bakkenes L, Jansen HAPM, In't Veld PH,

Beumer RR, Zwietering MH, Van Leusden FM. 2011. Consumption of raw vegetables and fruits: a risk factor for Campylobacter infections. *International journal of food microbiology*. vol 144(3): 406-412. doi: https://doi.org/10.1016/j.ijfoodmicro.2010.10.027. Xanthopoulos V, Tzanetakis N, Litopoulou-Tzanetaki E. 2010. Occurrence and characterization of Aeromonas hydrophila and Yersinia enterocolitica in minimally processed fresh vegetable salads. *Food Control.* vol 21(4): 393-398. doi: https://doi.org/10.1016/j.foodcont.2009.06.021.